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We have identified a putative coiled-coil motif within the amino-terminal half of the ebolavirus VP35 protein. Cross-linking studies
demonstrated the ability of VP35 to form trimers, consistent with the presence of a functional coiled-coil motif. VP35 mutants lacking the
coiled-coil motif or possessing a mutation designed to disrupt coiled-coil function were defective in oligomerization, as deduced by co-
immunoprecipitation studies. VP35 inhibits signaling that activates interferon regulatory factor 3 (IRF-3) and inhibits (IFN)-a/h production.
Experiments comparing the ability of VP35 mutants to block IFN responses demonstrated that the VP35 amino-terminus, which retains the
putative coiled-coil motif, was unable to inhibit IFN responses, whereas the VP35 carboxy-terminus weakly inhibited the activation of IFN
responses. IFN-antagonist function was restored when a heterologous trimerization motif was fused to the carboxy-terminal half of VP35,
suggesting that an oligomerization function at the amino-terminus facilitates an ‘‘IFN-antagonist’’ function exerted by the carboxy-terminal
half of VP35.
D 2005 Elsevier Inc. All rights reserved.Keywords: Homo-oligomerization; Interferon; Ebolavirus VP35 proteinEbola virus infection can cause severe hemorrhagic fever
in human and non-human primates (Sanchez et al., 2001).
The molecular mechanisms of ebolavirus pathogenesis
remain incompletely understood although several potential
mechanisms contributing to virulence have been reviewed
(Mahanty and Bray, 2004). These mechanisms include
cytotoxicity of the viral glycoprotein (GP), the production
of pro-inflammatory cytokines and the disregulation of the
coagulation cascade due to the production of tissue factor
(Chan et al., 2000; Geisbert et al., 2003a, 2003b; Sullivan et
al., 2005; Volchkov et al., 2001; Yang et al., 2000). Each of
these processes, however, likely occurs as a result of the
active replication of the virus. Thus, the ability of the virus
to counteract early antiviral responses, including the
interferon (IFN)-a/h system, is likely to play an important
role in ebolavirus virulence (Mahanty and Bray, 2004).0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.06.044
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E-mail address: chris.basler@mssm.edu (C.F. Basler).Several studies have demonstrated that ebolavirus
infection inhibits host IFN responses, preventing infected
cells from responding to IFN and also impairing IFN
production (Gupta et al., 2001; Harcourt et al., 1998,
1999). Expression of the VP35 protein of either Zaire
ebolavirus or Reston ebolavirus inhibited host cell inter-
feron-a/h (IFNa/h) responses (Basler et al., 2000, 2003).
VP35 can functionally substitute for another viral ‘‘IFN-
antagonist’’, the influenza A virus NS1 protein and can
inhibit production of IFNh induced by several stimuli,
including Sendai virus (SeV) infection or dsRNA trans-
fection (Basler et al., 2000). Inhibition of host IFN
responses appears to occur, at least in part, because
VP35 is able to prevent the phosphorylation that leads to
the activation of interferon regulatory factor 3 (IRF-3)
(Basler et al., 2003), a cellular transcription factor that
plays a critical role in the virus-mediated activation of the
IFNa/h gene (Schafer et al., 1998; Wathelet et al., 1998;
Weaver et al., 1998). Consistent with these observations,
ebolavirus infection does not activate IRF-3 (Basler et al.,05) 179 – 189
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inhibited production of IFN in human dendritic cells (Bosio
et al., 2003), and mutation of specific basic residues within
the carboxy-terminal half of VP35 impairs its ability to
inhibit Sendai virus-induced IFNa/h responses (Hartman
et al., 2004).
In addition to its IFN-antagonist activity, VP35 is an
essential component of the viral RNA-dependent RNA
polymerase complex, where it is an ortholog of para-
myxovirus and rhabdovirus phosphoproteins. VP35 also
plays an important structural role in the virus (Huang et al.,
2002; Muhlberger et al., 1998; Watanabe et al., 2004).
Despite its importance for ebolavirus replication, relatively
little information is available regarding functionally impor-
tant regions of VP35.
The present study demonstrates that VP35 forms
homooligomers and that a putative coiled-coil domain
within the amino-terminal half of VP35 is required for this
property. Further, we demonstrate that although the
carboxy-terminal half of VP35 contains sequences suffi-
cient to inhibit Sendai virus-induced IFNa/h responses,
oligomerization is required for full VP35 ‘‘IFN-antagonist
function’’.Results
The Zaire ebolavirus VP35 protein forms oligomers
The amino acid sequence of Zaire ebolavirus VP35
was analyzed with COILS, a computer program that
predicts coiled-coil domains (Lupas et al., 1991). COILS
predicted with high probability a single coiled-coil domain
between amino acids 82–118 of the 340 amino acid of
the VP35 protein (Fig. 1A). Thus, we hypothesized that
the predicted coiled-coil domain may mediate VP35
oligomerization.
To address the possibility that VP35 oligomerizes,
FLAG-tagged VP35 (FLAG-VP35) was partially purified
from transfected cells and fractionated on a Superdex-200
gel filtration column. Column fractions were collected and
analyzed by SDS-PAGE. Silver staining and Western blot
analysis revealed that VP35 eluted in four fractions with a
peak in the 126–194 kDa range, suggesting the formation
of a trimeric–tetrameric complex (Fig. 1B). Silver stained
gels did not show detectable co-purifying proteins, suggest-
ing that VP35 forms homo-oligomers (Fig. 1B).
The oligomeric form of the purified Flag-VP35 was
further analyzed following cross-linking with Dithiobis
(succinimidylpropionate) (DSP). The partially purified
Flag-VP35 was mock-treated or treated with 1, 2 or 5
AM DSP following standard procedures, then briefly
centrifuged and analyzed by Western blot with an anti-
VP35 antibody (Fig. 1C). After cross-linking with either
1 or 2 AM DSP, VP35 migrated at an apparent molecular
weight of approximately 124 kDa (based on the migrationof the band in the 2-AM lane). This observation is most
consistent with the formation of VP35 homo-trimers (Fig.
1C). Notably, however, increasing the DSP concentration
reproducibly resulted in a loss in the amount of VP35
protein visible on gels (Fig. 1C). This suggests that, in
addition to trimers, larger aggregates of VP35 were also
cross-linked such that they were too large to enter the
gel. Given that significant amounts of VP35 in a form
larger than 200 kDa were not detected during gel
filtration experiments (Fig. 1B), it is likely that the
majority of VP35 is trimeric. However, it should also be
noted that under the non-reducing electrophoresis con-
ditions used to analyze the mock cross-linked VP35,
variable amounts of higher molecular weight forms were
detected, although what these form represent in terms of
the oligomeric state of VP35 is unclear (Fig. 1C). Based
on these results, we conclude that VP35 forms trimers,
but we cannot exclude the formation of additional higher-
order oligomers as well.
The predicted coiled-coil domain is required for oligomer
formation
To determine whether the predicted coiled-coil domain is
required for VP35 oligomer formation, several VP35
mutants were constructed (Fig. 2A) and screened for their
ability to interact with wild-type VP35 (Fig. 2B). Coimmu-
noprecipitation analysis demonstrated that FLAG-VP35
interacted with both full-length HA-VP35 and with HA-
VP351–170, a truncation mutant containing the predicted
coiled-coil domain but lacking amino acids 171–340 (Fig.
2B, lanes 2 and 5). In contrast, HA-VP35171–340, lacking
the amino-terminal 170 amino acids, did not detectably
interact with FLAG-VP35 (Fig. 2B, lane 6). Mutant, HA-
VP35D82–118, deleted of the predicted coiled-coil domain,
was also unable to interact with FLAG-VP35 (Fig. 2B, lane
3). An additional mutant, HA-VP35L90/93/107A, in which key
leucines in the ‘‘a’’ and ‘‘d’’ positions of the predicted
coiled-coil domain were substituted with alanine, was also
unable to interact with FLAG-VP35 (Fig. 2B, lane 4).
Expression of each of the proteins analyzed in this experi-
ment was confirmed by Western blot (Fig. 2B). Notably,
when total lysates were probed with anti-HA antibody,
multimeric forms of VP35 molecules were seen in those
lanes containing either full-length VP35 or the amino-
terminal half of VP35. In contrast, VP35 mutants lacking
the coiled-coil domain or possessing a mutant coiled-coil
domain do not produce slower migrating forms, suggesting
that they have lost their ability to form SDS-stable
oligomers.
Using constructs analogous to those used for the co-
immunoprecipitation experiments, coiled-coil domain medi-
ated interactions were further validated using the mam-
malian two-hybrid system (data not shown). Thus, the
predicted coiled-coil domain contributes to VP35 oligomer
formation.
Fig. 1. VP35 forms oligomers. (A) Output from analysis of the Zaire ebolavirus VP35 protein by the COILS program. The x axis represents the 340 amino acid
VP35 sequence, and the y axis represents the probability (with 1 = 100%) that an amino acid residue is within a coiled-coil region. Different size scanning
windows are indicated by different lines as shown in the inset. Window sizes are 14 (dashed line), 21 (dotted line) and 28 (solid line) residues. (B) Gel filtration
analysis of VP35. Purified FLAG-VP35 was fractionated on a Superdex-200 fast-performance liquid chromatography column (Amersham Biosciences).
Collected gel filtration fractions were analyzed by silver stain (top) and by Western blot with anti-VP35 monoclonal antibody (bottom). The indicated fractions
correspond to the following approximate molecular weights: fraction 17–194 kDa; 18–126 kDa; 19–81 kDa; and 20–52 kDa. Molecular weights were
estimated by comparison to protein standards chymotrypsinogen A (19.9 kDa), bovine serum albumin (67 kDa), catalase (232 kDa), ferritin (440 kDa) and
thyroglobulin (670 kDa). (C) DSP cross-linking analysis of VP35. Purified FLAG-VP35 was cross-linked with 0, 1, 2 or 5 mM DSP for 30 min and
subsequently subjected to SDS-PAGE analysis under nonreducing conditions. The calculated molecular weights for each band are indicated by the arrows
pointing to the corresponding band. Western blotting of gel filtration and cross-linking samples were performed using a monoclonal anti-VP35 antibody (6C5).
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function
We have previously demonstrated that VP35 can inhibit
the SeV-induced activation the IRF-3 responsive promoter
ISG54 (Basler et al., 2000). We therefore assessed the IFN-
antagonist function of VP35 mutants with this assay. 293Tcells were transfected with an ISG54-CAT reporter, a
constitutively expressed Renilla luciferase plasmid pRL-tk
(Promega) and expression plasmids. The expression plas-
mids included an empty vector, a plasmid encoding wild
type VP35 and plasmids encoding the two truncation
mutants, HA-VP351–170 and HA-VP35171–340. Twenty-four
hours post-transfection, the cells were either mock infected
Fig. 2. VP35–VP35 interaction requires the predicted coiled coil domain. (A) A schematic illustration of the wild-type and mutant forms of VP35 used for
these experiments is presented. CCR, putative coiled-coil region. Foldon, foldon trimerization domain (see text). (B) 293T cells were transfected with
expression plasmids encoding the indicated proteins. Twenty-four hours post-transfection cells were harvested and lysed. The prepared lysates were
immunoprecipitated (IP) using anti-FLAG antibody (Sigma). After SDS-PAGE, Western blotting was performed using anti-HA antibody (Sigma). Expression
of HA and FLAG-tagged constructs was confirmed by Western blot analysis, with anti-HA and anti-FLAG tag antibodies, as is shown in the middle and lower
panels. Note that oligomeric forms of wt VP35 and VP351– 170 molecules are seen in the lower panel depicting the anti-HAWestern blot of total cell lysates.
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IRF-3, at a multiplicity of infection of 10. Subsequently,
ISG54-CAT reporter activity was determined and normal-
ized to Renilla luciferase activity. Infection of cells trans-
fected with empty vector resulted in a striking up-regulation
of this IRF-3-responsive reporter (Fig. 3A). As previously
reported, wild type VP35 was able to inhibit reporter
activation. Interestingly, when transfected in relatively large
amounts (2.5 Ag/106 cells), the oligomerization-deficient
mutant HA-VP35171–340 inhibited activation of the reporter,
while HA-VP351–170, which retained an ability to interactwith full-length VP35 (Fig. 2B), was unable to inhibit
activation of the reporter (Fig. 3A).
Although HA-VP35171–340 retained some function as an
IFN antagonist when large amounts of plasmid were trans-
fected, it was of interest to determine whether VP35 oligomer
formation, mediated by the amino-terminus of VP35,
contributes to its IFN antagonist function. Thus, a heterolo-
gous trimerization domain, the ‘‘foldon’’ domain, was fused to
HA-VP35171–340 (Fig. 2A). The foldon trimerization domain
is a small globular domain derived from the carboxy-terminus
of bacteriophage T4 fibritin protein which has been demon-
Fig. 3. Ability of full length and mutant VP35 constructs to inhibit activation of an IRF-3 responsive promoter. (A, B) Cells were co-transfected with empty
expression plasmid or plasmids expressing the indicated wild-type or mutant VP35s along with an ISG54 promoter-driven CAT reporter gene and a constitutively
expressed Renilla luciferase reporter plasmid. One day post-transfection, the cells were infected with SeV (moi = 10) and, the following day, reporter gene activity
was measured. Virus-induced ISG54 reporter values were normalized to the luciferase activity of a Renilla luciferase expressing plasmid. Results are presented as
fold-induction of the ISG54 reporter relative to an empty vector-transfected, mock-infected control. In panel A, all dishes received 2.5 Ag of expression plasmid. In
panel B, 25 or 250 ng of expression plasmid (expressing empty vector (empty), full-length VP35 (VP35), VP35171 – 340 (171–340) or Foldon-VP35171 – 340
(Foldon 171–340)) were transfected (concentrations indicated by wedges). For these experiments, empty vector was used to adjust all transfections to the same
final DNA concentration. For both A and B, the error bars indicate standard deviation. In panel A, values not statistically different, as determined by a Student’s t
test ( P  0.05) are indicated by identical symbols (* and #). In panel B, the values for empty vector (empty)- and the 171–340 (25 ng concentration)-transfected
samples are statistically different from each other and all other samples, as determined by Student’s t test ( P  0.05). (C) Western blot analysis of the indicated
expression plasmids is provided (following transfection of 250 ng or 25 ng). The relative expression levels of these proteins are highly reproducible. (D)
Expression of HA-VP35171 – 340 and Foldon-HA-VP35171 – 340 to verify trimer formation of Foldon-VP35171 – 340 construct. Lysates from cells transfected with the
indicated construct were subjected Western blot analysis with anti-HA antibody (Sigma). These samples were not boiled prior to electrophoresis.
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proteins (e.g., Frank et al., 2001; Stevens et al., 2004). The
foldon domain was fused to the amino terminus of HA-
VP35171–340 (Foldon-HA-VP35171–340), and the ability of the
this construct to inhibit virus-induced activation of the reporter
was compared to the IFN-antagonist activities of full-length
VP35 and to VP35171–340. Addition of the foldon domain
enhanced the IFN-antagonist activity of the VP35 carboxy-
terminus (Fig. 3B). This difference is most easily seenwhen the
amounts of protein produced by the various constructs are
compared. The Foldon-VP35 plasmid produces modestly
more protein/microgram of plasmid DNA than either wild-type VP35 or HA-VP35171–340. However, the foldon-HA-
VP35171–340 25 ng sample (where relatively little protein is
present) displays an IFN-antagonist activity at least as strong as
that seen in the 250 ng HA-VP35171–340 sample (where much
more protein is present). Thus, these data support the
conclusion that the foldon domain restores activity to the
carboxy-terminal half ofVP35. As a control, the foldon domain
was fused to the amino-terminus of VP351–170. When this
construct was tested for IFN-antagonist activity with the same
reporter gene assay, it exhibited no ability to inhibit SeV-
induced gene expression (data not shown). Thus, the foldon
domain does not appear to act, on its own, as an IFN-
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carboxy-terminal half of VP35 to oligomerize is supported by
SDS-PAGE analysis of samples that were not boiled prior to
electrophoresis, where the foldon domain construct yields
higher molecular weight bands (Fig. 3D).
To determine whether these constructs also inhibit
production of endogenous IFN, an IFN bioassay was
performed. 293T cells were transfected with different
amounts of either empty vector or plasmids expressing wild
type VP35, VP35171–340 or Foldon-VP35171–340. One day
post-transfection, the cells were infected with SeV (moi =
10). One day following this infection, supernatants were
harvested, clarified by centrifugation and exposed to ultra-
violet (UV) light to inactivate infectious virus. A series of
two-fold dilutions of these UV inactivated supernatants were
then added to Vero cells. One day post-treatment, the Vero
cells were infected with a green fluorescence protein (GFP)-
expressing Newcastle disease virus (NDV-GFP). The pres-
ence of IFN in the supernatants of the transfected 293T cells,
leads to suppression of NDV-GFP replication and hence toFig. 4. An interferon bioassay demonstrates that the foldon motif restores to VP35
transfected with the indicated amounts (left of the figure) of expression plasmids e
expression plasmid in all transfections was adjusted to 2500 ng with empty vecto
panels). 24 hours post-transfection, the 293T cells were mock infected or infected
cultures were collected, clarified by centrifugation and UV treated to inactivate
supernatants were transferred onto Vero cells at the indicated dilutions (1:256 or
subsequently infected with the NDV-GFP virus. IFN present in the 293T cell supern
and green fluorescence in the Vero cells. As the supernatants are diluted, an incre
(2500 ng) comparing the 1/256 and 1/512 dilutions). In the anti-IFNh panel, s
incubated with IFNh neutralizing antiserum prior to its addition to the Vero cells.
antiviral effect in these cells is mediated mainly by IFNh. The ‘‘Mock infected’’ co
and Foldon 171–340 indicate the expression plasmids transfected at the indicated a
SeV-induced expression of the IRF-3-responsive ISG56 gene, western blots were
Expression of p56, 24 hours post SeV-infection of cells transfected with 25, 250loss of GFP expression. This is illustrated in Fig. 4A where
the supernatants from empty vector-transfected, SeV-infected
293T cells induce in Vero cells an antiviral state (see empty
vector (2500 ng) panels, top). When neutralizing anti-IFNh
antibody was added to the supernatants from the empty
vector-treated, SeV-infected 293T cells, the antiviral effect
was lost, demonstrating that, in this experiment, the antiviral
effect is mediated by IFNh (Fig. 4, anti-IFNh panel).
When the different VP35 constructs were assessed,
significant suppression of IFN production was evident even
in the supernatants of cells transfected with as little as 25 ng
of VP35- or Foldon-VP35(171–340) expression plasmid (see
VP35 and Foldon-VP35(171–340) columns) (Fig. 4A). In
contrast, VP35(171–340) only detectably suppressed IFN
production when 2500 ng of plasmid were transfected (Fig.
4A). Thus, in this assay, the Foldon-VP35(171–340) construct
is 100 times more potent than the VP35(171–340) plasmid.
The relative ability of these mutants to affect activation
of an endogenous, IRF-3 responsive gene, the ISG56 gene
(Grandvaux et al., 2002), was also addressed (Fig. 4B).171 – 340 the ability to inhibit endogenous IFNh production. 293T cells were
ncoding VP35, VP35171 – 340, and Foldon-VP35171 – 340. The total amount of
r. As a control, cells were transfected with 2500 ng empty vector (top two
with SeV (moi = 10). One day post-infection media supernatants from all
any infectious SeV. A. To test for IFN antiviral activity, the inactivated
1:512, indicated by ‘‘Reciprocal of dilution’’). The treated Vero cells were
atants, induced by the prior SeV infection, inhibits replication of NDV-GFP
ase in GFP expression is seen (see the two uppermost panels, empty vector
upernatant from an empty vector-transfected, SeV-infected cells was pre-
The recovery of NDV-GFP replication in these cells demonstrates that the
ntrol panel denotes Vero cells without NDV-GFP infection. VP35, 171–340
mount (in ng/106 cells) (see Expression vector amounts at left). B. To assess
performed to examine levels of p56, the protein product of the ISG56 gene.
or 2500 ng of the indicated expression plasmids, is shown.
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ISG56 gene (Guo et al., 2000), was performed using an anti-
p56 polyclonal antiserum. Virus-induced p56 expression
was inhibited in cells transfected with as little as 25 ng of
either full-length VP35 plasmid or Foldon-HA-VP35171–340
plasmid. In contrast, 2.5 Ag of HA-VP35171–340 plasmid
was required to achieve comparable levels of inhibition
(Fig. 4B). It should be noted that none of the constructs
brought p56 expression levels to the baseline seen in empty
vector-transfected, mock-infected cells. This reflects the fact
that transfection efficiencies are not 100% resulting in the
presence of a pool of cells that do not receive any VP35
plasmid. In summary, these data are consistent with the
ability of the Foldon domain to restore IFN-antagonist
activity to the carboxy-terminal half of VP35.
To address the mechanism by which the foldon domain
restores the IFN-antagonist activity of VP35171–340, the
activation status of IRF-3 was examined. Upon viral
stimulation, the transcription factor IRF-3 is phosphorylated
by virus-activated kinases (Fitzgerald et al., 2003; Sharma et
al., 2003). Phosphorylated IRF-3 then homodimerizes and is
translocated to the nucleus where cofactors such as CBP/
p300 are recruited to initiate transcription of target genes
(Servant et al., 2002). Previously, we have shown that VP35
can prevent IRF-3 phosphorylation, IRF-3 dimerization and
thus IRF-3 activation (Basler et al., 2003). Similarly, Foldon-
HA-VP35171–340 displays the ability to inhibit IRF-3 dimer
formation at levels comparable to full-length HA-VP35 (Fig.
5). Although HA-VP35171–340 was also able to inhibit dimer
formation in comparison to the empty vector-infected cells,
the inhibition was significantly less than that seen with either
full-length VP35 or with Foldon-HA-VP35171–340. Thus, the
ability of these constructs to inhibit IRF-3 correlates with
their ability to inhibit ISG54 promoter activation, IFNh
production and p56 expression. Although we correlate this
activity with inhibition of IRF-3, we cannot exclude the
possibility that VP35 also targets other components of the
IFN response as well. Taken together, these data indicate thatFig. 5. The Foldon trimerization motif restores the ability of VP35171 – 340 to
block IRF-3 activation. 293Tcells were transfected with the indicated protein
expression plasmids (full length VP35 (VP35), VP35171 – 340 (171–340)
or Foldon-VP35171 – 340 (Foldon 171–340) and either mock-infected of
infected with Sendai virus (SeV) 24 h post-transfection. Ten hours post-
infection cells were harvested and lysed. For IRF-3 analysis, cells were
subjected to native PAGE analysis as previously described (Iwamura et al.,
2001) followed by blotting with an anti-IRF-3 monoclonal antibody.the carboxy-terminus of VP35 exhibits partial IFN antagonist
function and that oligomerization enhances this activity.Discussion
Numerous antagonists of the IFN response have now
been described, including many encoded by negative-strand
RNA viruses (Garcia-Sastre, 2004). The biological signifi-
cance of such molecules is highlighted by their importance
for virulence and virus host range. For example, mutants of
influenza A viruses (Garcia-Sastre et al., 1998), bunyam-
wera virus (Bridgen et al., 2001), vaccinia virus (Brandt and
Jacobs, 2001), herpes simplex virus type 1 (HSV-1) (Chou
et al., 1990; Leib et al., 1999) and Rift Valley Fever virus
(Bouloy et al., 2001) which lack or which possess altered
viral interferon-antagonists, are attenuated in mice. In
addition, species-specific abilities to counteract host inter-
feron responses have been demonstrated for several para-
myxoviruses (e.g., Bossert and Conzelmann, 2002; Parisien
et al., 2002; Park et al., 2003; Young et al., 2001). Because
of their importance for virulence, IFN-antagonists could
potentially serve as targets for novel antivirals, and muta-
genesis of IFN-antagonists has been suggested as a strategy
for the rational generation of live, attenuated vaccine strains
(Garcia-Sastre, 2004).
The present study demonstrates that VP35 multimerizes,
forming homotrimers, that a putative coiled-coil domain
appears to be required for efficient homooligomerization
and that this region facilitates the ‘‘IFN-antagonist’’ function
of the protein. The carboxy-terminal half of VP35 contained
sequences that were sufficient, when fused even to a
heterologous trimerization motif, to fully inhibit IRF-3
activation. Our data are consistent with the observations of
Hartman et al. (2004) who found that mutation of individual
basic residues within the VP35 carboxy-terminus impaired
VP35 function. However, this previous study did not
exclude a requirement for amino-terminal portions of
VP35 in this function. Our data clearly demonstrate that
the carboxy-terminal half of VP35 has sufficient informa-
tion to prevent activation of IRF-3, provided an oligome-
rization function is present. The method described here,
fusion of a heterologous oligomerization motif to deletion
mutants of VP35, should facilitate the further definition of a
minimal ‘‘IFN-antagonist domain’’.
These observations regarding the regions of VP35
required for its IFN-antagonist activity have implications
for the mechanism by which VP35 blocks IFN responses
and for the generation of ebolaviruses lacking this function.
Although the precise targets of VP35 remain to be defined,
our previous data indicate that VP35 can inhibit virus-
induced IRF-3 activation. With our present observations, we
can hypothesize that the carboxy-terminal half of VP35
interacts with a component(s) of the virus-induced pathways
activating IRF-3 and that oligomerization stabilizes this
interaction. Recently identified proteins that can be con-
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helicases RIG-I and MDA-5. These proteins appear to
participate in the detection of virus infection and in the
subsequent activation of IRF-3 (Andrejeva et al., 2004;
Sumpter et al., 2005; Yoneyama et al., 2004). Interestingly,
the V proteins of several paramyxoviruses were found to
inhibit signaling by MDA-5 and to interact with MDA-5
(Andrejeva et al., 2004), explaining their ability to inhibit
IFNh production (He et al., 2002; Poole et al., 2002). In
addition, RIG-I regulates permissiveness of cells for
hepatitis C virus (HCV) replicons, and the HCV NS3/4A
protease inhibits RIG-I signaling (Foy et al., 2005). It will of
interest to determine whether VP35 interacts with these
cellular proteins and whether multimerization of VP35 is
required for any such interactions.
As noted above, VP35 is multifunctional. In addition to
its anti-IFN properties, it is analogous to the phosphoprotein
(P) of rhabdoviruses and paramyxoviruses in that it is
encoded at the same position within genome (i.e., by the
gene which follows the nucleoprotein (N) gene) and because
it acts as a co-factor for the viral RNA-dependent RNA
polymerase in the transcription and replication of viral genes
(Muhlberger et al., 1998). Like VP35, paramyxovirus and
rhabdovirus P proteins possess coiled-coil domains. The
coiled-coil domains of the paramyxovirus P proteins
reportedly mediate formation of homotrimers or homote-
tramers, which parallels our observations with VP35
(Choudhary et al., 2002; Curran et al., 1995; Rahaman et
al., 2004; Tarbouriech et al., 2000). The ability of P proteins
to oligomerize appears to be of functional importance for
paramyxovirus RNA synthesis (e.g., Choudhary et al., 2002;
Rahaman et al., 2004). It will also be of interest to determine
whether the coiled-coil domain of VP35 is required for
ebolavirus RNA synthesis.
The most straightforward means of evaluating the
importance of VP35’s IFN-antagonist activity will be the
generation of recombinant ebolaviruses lacking this activity,
and methods exist to generate such recombinant viruses
from cDNA (Neumann et al., 2002; Towner et al., 2005;
Volchkov et al., 2001). However, the multifunctional nature
of VP35 complicates the generation of such a virus. The
data described above should facilitate the further definition
of those portions of the protein required for this function.
The present studies may therefore facilitate the generation of
‘‘IFN-antagonist deficient’’ ebolaviruses.Materials and methods
Cells, viruses and plasmids
293T cells were maintained in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 units/ml penicillin G and 100 Ag/ml
streptomycin. Sendai virus strain Cantell was grown in 10-
day-old embryonated chicken eggs at 37 -C for 48 h. Theplasmid pCAGGS-HA-VP35 was derived from pcDNA3-
EboVP35 (Basler et al., 2000) and was used to generate all
HA-VP35 mutants utilized in this study. Additionally,
pCAGGS-human IRF-3 was previously described (Basler
et al., 2003). A plasmid containing the ‘‘Foldon’’ domain was
kindly provided by James Stevens and Ian Wilson (The
Scripps Research Institute).
Western blot analysis
293T cells were transfected using Lipofectamine 2000
(LF2000) (Invitrogen) as previously described (Basler et al.,
2003). Briefly, cells were transfected in suspension with 1 Ag
of pCAGGS-hIRF-3 and 2.5 Ag of the indicated expression
plasmids. Twenty-four hours post-transfection cells were
infected with SeV or mock infected. Ten hours post-
infection cell lysates were prepared in a modified RIPA
lysis buffer (50 mM Tris–HCl [pH 7.4], 150 mM NaCl,
1 mM EDTA, 1% NP-40, 0.25% DOC, 1 mM sodium
orthovanadate and Roche protease inhibitor cocktail). The
lysates were then subjected to native gel electrophoresis as
described previously (Iwamura et al., 2001). After electro-
phoresis IRF-3 was detected by Western blot analysis with
polyclonal anti-IRF-3 antibody FL-425 (Santa Cruz Bio-
technology) diluted 1:500.
Western blot detection of p56 expression was performed
with an anti-p56 antibody kindly provided by Dr. Ganes Sen
(The Cleveland Clinic Foundation).
Gel filtration
293T cells were transfected with LF2000 and 3 Ag of
FLAG-VP35 expression plasmid. Forty-eight hours post-
transfection cell lysates were prepared in 0.25 mM Tris–HCl
(pH 8.0), 500 mMKCl, 0.5 mM EDTA, 10% glycerol, 1 mM
DTT, 0.05% Triton X-100 and Roche protease inhibitor
cocktail and incubated with 75 Al of a 50% slurry of anti-
FLAG-M2 affinity gel (Sigma) for 2 h at 4 -C. FLAG-VP35
was then eluted with 100 Ag/ml FLAG peptide (Sigma) in 50
Mm Tris–HCl (pH 8.0), 150 mM NaCl, 10% glycerol, 5
mM DTT and 0.1% SDS. The eluant was loaded onto a
Superdex-200 column (Amersham Biosciences). Collected
fractions were then subjected to Western blotting with
monoclonal anti-VP35 antibody (6C5) diluted 1:10,000
and to SDS-PAGE and silver stain analysis (Invitrogen).
Cross-linking
293T cells were transfected with LF2000 and 8 Ag of
FLAG-VP35 expression plasmid. Forty-eight hours post-
transfection cell lysates were prepared in 50 mM Tris–HCl
(pH 8.0), 280 mM NaCl, 0.2 mM EDTA, 2.0 mM EGTA,
10% glycerol, 0.05% Igepal CA-630, 0.1 mM Sodium
Orthovanadate, 1 mM DTT and Roche protease inhibitor
cocktail and incubated with 75 Al of a 50% slurry of anti-
FLAG-M2 affinity gel (Sigma) for 2 h at 4 -C. FLAG-VP35
S.P. Reid et al. / Virology 341 (2005) 179–189 187was then eluted with 100 Ag/ml FLAG peptide (Sigma) in
the same buffer. The membrane permeable and thiol-
cleavable cross-linker Dithiobis[succinimydylpropionate]
(DSP) (Pierce) was prepared as a 25 mM stock solution in
dimethyl sulfoxide (DMSO). The eluant was then incubated
for 30 min at room temperature with DSP at a final
concentration of 0, 1, 2 or 5 mM. The reaction was
quenched by the addition of 20 mM Tris–HCl pH 7.5 for 15
min at room temperature. The samples were then subjected
to SDS-PAGE analysis under nonreducing conditions and
subsequent Western blot analysis with monoclonal anti-
VP35 antibody (6C5) diluted 1:5000. Molecular weight
determinations were made using the AlphaImager 3400,
AlphaEase FC software (Alpha Innotech).
Co-immunoprecipitation assays
293T cells were transfected using LF2000 with 2 Ag of
the indicated expression plasmids. Twenty-four hours post-
transfection cell lysates were prepared in modified RIPA
lysis buffer (see above) and subsequently incubated with 50
Al of a 50% slurry of anti-FLAG-M2 affinity gel (Sigma) for
2 h at 4 -C. Bound lysates were subjected to Western blot
analysis with monoclonal anti-HA antibody (Sigma) diluted
1:5000 and M2 anti-FLAG antibody (Sigma) diluted
1:5000.
Reporter gene assays
293T cells were transfected using LF2000 with either
2.5, 0.25 or 0.025 Ag of the indicated expression plasmids
along with 0.3 Ag of the CAT reporter vector pHISG-54-
CAT and 0.3 Ag of an expression plasmid that constitutively
expresses the Renilla luciferase reporter vector pRL-tk
(Promega). Twenty four hours post-transfection cells were
infected with SeV or mock-infected. Twelve hours post-
infection cells were analyzed as previously described
(Basler et al., 2003).
In addition, cell lysates were subjected to SDS-PAGE and
subsequent Western blot analysis with polyclonal anti-p56
antiserum diluted 1:2000 or, to verify expression of wildtype
VP35, HA-VP35171–340 and Foldon-HA-VP35171–340, with
a monoclonal anti-HA antibody (Sigma).
IFN Bioassay
293T cells were transfected with different concentrations
of either empty vector or plasmids expressing wild type
VP35, VP35(171–340) or Foldon-VP35(171–340). One day
post-transfection, the cells were infected with SeV (moi =
10). One day following this infection, supernatants were
harvested, clarified by centrifugation and exposed to ultra-
violet (UV) light to inactivate infectious virus. A series of
two-fold dilutions of these UV inactivated supernatants were
then added to Vero cells. One day post-treatment, the Vero
cells were infected with a green fluorescence protein (GFP) -expressing Newcastle disease virus (NDV-GFP) at an moi =
6. The presence of IFN in the supernatants of the transfected
and SeV infected 293T cells, leads to suppression of NDV-
GFP replication and hence to loss of GFP expression in the
treated Vero cells. In contrast, when the IFN response is
suppressed by expression of a particular protein or is
neutralized by addition of an anti-IFNh antibody, NDV-
GFP replication is restored.Acknowledgments
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